News

Lantheus Announces FDA Acceptance of NDA for New Formulation for Market-Leading PSMA PET Imaging Agent
Designed to expand PSMA PET imaging access for patients by increasing batch size by ~50% and enhancing supply resiliencePDUFA date set for March 6, 2026 BEDFORD, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) ...
Applied Clinical Trials Online1d
How Integrated Systems Help Biotechs Stay Inspection-Ready
In this video interview, Luke Wilson, senior director, biotech, pharma services at Thermo Fisher Scientific, discusses how ...
TransMedics Receives FDA IDE Approval to Initiate Next-Generation OCS Heart Trial
TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today ...
Denali Therapeutics Inc. (DNLI) Secures FDA Priority Review for First-Ever Brain-Penetrant Hunter Syndrome Therapy
We recently compiled a list of 11 Best Future Stocks to Buy Now. Denali Therapeutics Inc. stands sixth on our list among the ...